Oxford University Professor Sarah Gilbert, who led the development of the vaccine against coronavirus AZD1222, evaluated the combination of the British drug with Sputnik V.
According to her, AZD1222 may be more effective in combination with other drugs, including the Russian vaccine. She added that this would be explored in a relatively “small study.”
Earlier, the British pharmaceutical company AstraZeneca announced the start of clinical trials of a combination of its AZD1222 vaccine and the Russian drug Sputnik V. The AZD1222 vaccine was developed based on an adenovirus vector, a genetically modified adenovirus. Adenoviral vectors with embedded coronavirus S-protein are also the basis of the two-component Sputnik V vaccine.